Giulia Liccioli1, Edoardo Marrani2, Teresa Giani2, Gabriele Simonini2, Simona Barni3, Francesca Mori3. 1. Allergy Unit, Department of Pediatrics, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy, giulialiccioli@gmail.com. 2. Rheumatology Unit, Department of Pediatrics, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy. 3. Allergy Unit, Department of Pediatrics, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy.
Abstract
INTRODUCTION: Acute generalized exanthematous pustulosis (AGEP) is a generalized, non-follicular sterile pustular rash, categorized as a severe cutaneous adverse reaction, which usually has a favorable prognosis. In a majority of cases (90%), AGEP is drug induced and different drugs are reported as cause of AGEP. Hydroxychloroquine (HCQ) is an antimalarial drug that is also used in some dermatologic and rheumatic diseases due to its immunosuppressive actions. Some cases of AGEP induced by HCQ are reported in literature but only in adults. MATERIALS, METHODS AND RESULTS: We describe the first case of AGEP caused by HCQ in a child affected by juvenile Sjögren syndrome. After withdrawal of HCQ and subsequent administration, the patient experienced the same cutaneous reaction. An allergy work-up was performed and patch test showed an ectopic flare of AGEP eruption. CONCLUSION: Our patient represents the first pediatric case of AGEP to HCQ, posing such a drug as a possible trigger also in children. Therefore, an accurate drug medical history is mandatory in order to rule out potential drug reactions when facing a sudden rash.
INTRODUCTION:Acute generalized exanthematous pustulosis (AGEP) is a generalized, non-follicular sterile pustular rash, categorized as a severe cutaneous adverse reaction, which usually has a favorable prognosis. In a majority of cases (90%), AGEP is drug induced and different drugs are reported as cause of AGEP. Hydroxychloroquine (HCQ) is an antimalarial drug that is also used in some dermatologic and rheumatic diseases due to its immunosuppressive actions. Some cases of AGEP induced by HCQ are reported in literature but only in adults. MATERIALS, METHODS AND RESULTS: We describe the first case of AGEP caused by HCQ in a child affected by juvenile Sjögren syndrome. After withdrawal of HCQ and subsequent administration, the patient experienced the same cutaneous reaction. An allergy work-up was performed and patch test showed an ectopic flare of AGEP eruption. CONCLUSION: Our patient represents the first pediatric case of AGEP to HCQ, posing such a drug as a possible trigger also in children. Therefore, an accurate drug medical history is mandatory in order to rule out potential drug reactions when facing a sudden rash.
Authors: Parnian Jamshidi; Bahareh Hajikhani; Mehdi Mirsaeidi; Hassan Vahidnezhad; Masoud Dadashi; Mohammad Javad Nasiri Journal: Front Med (Lausanne) Date: 2021-02-16
Authors: Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden Journal: J Clin Med Date: 2022-01-13 Impact factor: 4.241